Targets › HER2
9 programs from 9 companies in 10 trials: 9 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. (UniProt, P04626)
Open in Phaseline: the race on HER2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Washington | pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine (WOKVAC) Plasmid DNA vaccine encoding tumor-associated antigens (IGFBP2, HER2, IGF1R) to stimulate | IGFBP2, HER2, IGF1R | Phase 2 | Anatomic Stage I Breast Cancer AJCC v8 | Dec 2026 |
| City of Hope Medical Center | HER2(EQ)BBζ/CD19t+ T cells CAR-T cell therapy targeting HER2 with co-stimulatory BBζ domain and CD19 marker | HER2 | Phase 1 | Glioblastoma | Dec 2026 |
| Beijing Biotech | EB-DUO-CAR-NK-CEA/GCC Dual-target CAR-NK cell therapy targeting CEA and GUCY2C (or CEA and HER2, or GUCY2C and H | CEACAM5, GUCY2C, ERBB2, CEA, HER2, IL15 | Phase 1 | Colorectal Cancer; Colorectal Cancer Metastatic | Mar 2027 |
| Changchun GeneScience Pharmaceutical | GenSci139 bispecific antibody drug conjugate targeting EGFR and HER2 | EGFR, HER2 | Phase 1 | Advanced Solid Tumors | Jul 2028 |
| Bayer | BAY2927088 (sevabertinib) Tyrosine kinase inhibitor targeting mutated EGFR and HER2 | EGFR, HER2 | Phase 1 | Advanced Non-small Cell Lung Cancer | Dec 2028 |
| BlossomHill Therapeutics | BH-30643 Dual EGFR/HER2 inhibitor | EGFR, HER2 | Phase 1 | NSCLC (Advanced Non-small Cell Lung Cancer) | Jan 2029 |
| University of Virginia | HER2 FPBMC Anti-CD3 x anti-HER2 bispecific antibody armed fresh peripheral blood mononuclear cells | HER2, CD3 | Phase 1 | Breast Cancer | Oct 2029 |
| Pierre Fabre Medicament | STX-721/PFL-721 Exon 20 insertion-selective tyrosine kinase inhibitor | EGFR, HER2 | Phase 1 | Non-Small Cell Lung Cancer | Dec 2029 |
| Vanderbilt-Ingram Cancer Center | [18F]NOTA-ABY-030 HER2-targeted PET imaging agent; anti-HER2 Affibody molecule labeled with fluorine-18 | HER2 | Phase 1 | HNSCC,Larynx, Pharynx and Oral Cavity | Jul 2031 |
Breast Cancer (1) HNSCC,Larynx, Pharynx and Oral Cavity (1) Colorectal Cancer (1) Colorectal Cancer Metastatic (1) NSCLC (Advanced Non-small Cell Lung Cancer) (1) Non-Small Cell Lung Cancer (1) Anatomic Stage I Breast Cancer AJCC v8 (1) Advanced Non-small Cell Lung Cancer (1) Glioblastoma (1) Advanced Solid Tumors (1)
small molecule (5), mixed (3), other (1)
University of Virginia (1) Vanderbilt-Ingram Cancer Center (1) Beijing Biotech (1) BlossomHill Therapeutics (1) Pierre Fabre Medicament (1) University of Washington (1) Bayer (1) City of Hope Medical Center (1) Changchun GeneScience Pharmaceutical (1)
EGFR (4) CD3 (1) CEACAM5 (1) GUCY2C (1) ERBB2 (1) CEA (1) IL15 (1) IGFBP2 (1) IGF1R (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.